Myeloid-Derived Suppressor Cells and Pulmonary Hypertension.

Bryant AJ, Mehrad B, Brusko TM, West JD, Moldawer LL
Int J Mol Sci. 2018 19 (8)

PMID: 30081463 · PMCID: PMC6121540 · DOI:10.3390/ijms19082277

Myeloid⁻derived suppressor cells (MDSCs) comprised a heterogeneous subset of bone marrow⁻derived myeloid cells, best studied in cancer research, that are increasingly implicated in the pathogenesis of pulmonary vascular remodeling and the development of pulmonary hypertension. Stem cell transplantation represents one extreme interventional strategy for ablating the myeloid compartment but poses a number of translational challenges. There remains an outstanding need for additional therapeutic targets to impact MDSC function, including the potential to alter interactions with innate and adaptive immune subsets, or alternatively, alter trafficking receptors, metabolic pathways, and transcription factor signaling with readily available and safe drugs. In this review, we summarize the current literature on the role of myeloid cells in the development of pulmonary hypertension, first in pulmonary circulation changes associated with myelodysplastic syndromes, and then by examining intrinsic myeloid cell changes that contribute to disease progression in pulmonary hypertension. We then outline several tractable targets and pathways relevant to pulmonary hypertension via MDSC regulation. Identifying these MDSC-regulated effectors is part of an ongoing effort to impact the field of pulmonary hypertension research through identification of myeloid compartment-specific therapeutic applications in the treatment of pulmonary vasculopathies.

MeSH Terms (7)

Animals Dendritic Cells Humans Hypertension, Pulmonary Myeloid-Derived Suppressor Cells Receptors, Interleukin-8B Signal Transduction

Connections (1)

This publication is referenced by other Labnodes entities: